Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Alana Hurwitz

Nurse Practitioner, Family Sun City, AZ Nurse Practitioner

NPI 1851931687 CMS profile 11186889

13640 N 99Th Ave Ste 100, Sun City, AZ 85351

Open in the dashboard

General payments

$24,893

1,488 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alana Hurwitz of Sun City, AZ is reported in the CMS Open Payments database as having received $24,893 across 1,488 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,952 327
2024 General $5,371 332
2023 General $5,361 341
2022 General $3,577 236
2021 General $3,631 252

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alana Hurwitz
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Alana Hurwitz were reported at $6,952. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Alana Hurwitz Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $3,631 $124 $35–$379 $132
2022 $3,577 $141 $44–$430 $149
2023 $5,361 $154 $49–$476 $160
2024 $5,371 $165 $51–$504 $164
2025 $6,952 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $3,145 185 payments
  2. UCB, Inc. $2,864 203 payments
  3. Biogen, Inc. $1,762 85 payments
  4. Teva Pharmaceuticals USA, Inc. $1,755 117 payments
  5. Novartis Pharmaceuticals Corporation $1,706 103 payments
  6. SK Life Science, Inc. $1,302 60 payments
  7. Alexion Pharmaceuticals, Inc. $1,283 44 payments
  8. Lilly USA, LLC $1,053 69 payments
  9. Amneal Pharmaceuticals LLC $1,001 86 payments
  10. Eisai Inc. $888 46 payments
  11. Other $8,134 490 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $23,913 1,476 payments
  2. Consulting Fee $475 3 payments
  3. Education $431 7 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $74 2 payments
Products named General payments · program years 2021–2025
  1. Briviact $1,334 114 payments
  2. UBRELVY $1,300 89 payments
  3. QULIPTA $1,255 79 payments
  4. KESIMPTA $1,152 55 payments
  5. ULTOMIRIS $1,117 33 payments
  6. Leqembi $874 45 payments
  7. TYSABRI $831 20 payments
  8. AJOVY $756 64 payments
  9. RYTARY $682 58 payments
  10. ZAVZPRET $673 37 payments
  11. Other $15,002 956 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 51 drugs

Part D claims

2,411

Median for Nurse Practitioner: 389

Drug cost

$248,220

Median for Nurse Practitioner: $21,885

Branded share of claims

19.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Botox Onabotulinumtoxina Brand 55 $77,575
Ubrelvy Ubrogepant Brand 31 $29,343
Nurtec Odt Rimegepant Sulfate Brand 23 $27,493
Ajovy Autoinjector Fremanezumab-Vfrm Brand 31 $25,518
Emgality Pen Galcanezumab-Gnlm Brand 19 $15,538
Qulipta Atogepant Brand 11 $15,141
Gabapentin Generic 223 $5,656
Pregabalin Generic 203 $5,545
Lacosamide Generic 47 $4,613
Memantine Hcl Generic 199 $4,158

The 10 drugs with the highest cost, of 51 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 34 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KESIMPTA
$424 — —
BOTOX
$339 55 —
Briviact
$308 — —
Rystiggo
$296 — —
ULTOMIRIS
$279 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 34 with Patron

Records

1,488 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record